Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 305 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Neoadjuvant Pembrolizumab Combined with Chemotherapy Followed by Adjuvant Pembrolizumab Significantly Improves... February 15, 2022 5 Kids Battling Sickle Cell And Cancer Model Their Dream Jobs... September 27, 2019 What to Know About Peer-Reviewed Cancer Information and Its Role in... August 10, 2022 Age: the forgotten cancer risk factor? May 29, 2023 Load more HOT NEWS Topical Diclofenac Gel Reduces the Incidence of Hand-Foot Syndrome in Patients... Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve... New Measures to Avoid Handling Errors with Leuprorelin Depot Medicines Hospital’s Team Of “Dog-Tors” Helps Sick Kids Feel Less Scared Of...
